Microbiome Modulator

Lacticaseibacillus paracasei

Lacticaseibacillus paracasei

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

1e10-1e11+ CFU/day equivalent (strain specific)

watchEffect Window

4-12 weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lacticaseibacillus paracasei is a strain-specific probiotic used for immune and GI support.

Human data suggest possible benefit in selected allergy, body-composition, or symptom contexts, but outcomes vary by strain and endpoint. Choose products linked to human RCTs and avoid class-wide assumptions.

Strain-specific probiotic signaling may influence gut-immune-metabolic pathways.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Strain-specific metabolic and adiposity effects
  • Possible immune/allergy symptom modulation

Secondary Outcomes

  • Effects vary by strain and host context
  • Mixed primary-endpoint consistency

Safety

Contraindications and Interactions

Contraindications

  • Severe immunocompromise without specialist guidance
  • Critical illness with invasive devices
  • Under 18 without clinical supervision

Side effects

  • Mild GI bloating/gas
  • Temporary stool-pattern changes
  • Rare infection risk in high-risk hosts

Interactions

  • Antibiotic timing can reduce probiotic viability
  • Multi-probiotic confounding
  • High-prebiotic GI burden overlap

Avoid if

  • High-risk medical fragility
  • No strain identity on product label
  • Inability to track target outcomes

Evidence

Study-level References

lacticaseibacillus-paracasei-SRC-001Double-blind randomized controlled trial
Sourceopen_in_new

Lin SW, et al. The Effects of Lactobacillus paracasei NB23 on IGF-1, Muscle Function, and Cardiometabolic Risk Factors in Healthy Individuals: A Randomized Trial. Probiotics Antimicrob Proteins. 2025. doi:10.1007/s12602-025-10604-4. PMID:40591241.

Population: Healthy adults

Dose protocol: 3 g twice daily containing 5 × 10^10 CFU, 12 weeks

Key findings: Improved selected metabolic/inflammatory and muscle-related markers

Notes: Single study and healthy-population scope

Paper content

Improved selected metabolic/inflammatory and muscle-related markers

lacticaseibacillus-paracasei-SRC-002Randomized double-blind placebo-controlled trial
Sourceopen_in_new

Yamamoto-Yamaya K, et al. The Effect of Heat-Killed Lacticaseibacillus paracasei K71 on Abdominal Fat Reduction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparative Trial. J Nutr Sci Vitaminol (Tokyo). 2025;71(5):486-497. doi:10.3177/jnsv.71.486. PMID:41183976.

Population: Adults with BMI >=23 and <30 (n=80)

Dose protocol: 50 mg heat-killed cells (~1 × 10^11) daily for 12 weeks

Key findings: Favorable adiposity-related changes in lifestyle-stable subgroup

Notes: Primary analysis mixed. Subgroup effects stronger

Paper content

Favorable adiposity-related changes in lifestyle-stable subgroup

lacticaseibacillus-paracasei-SRC-003Double-blind randomized crossover trial
Sourceopen_in_new

Perrin Y, et al. Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis. Clin Transl Allergy. 2014;4(1):1. doi:10.1186/2045-7022-4-1. PMID:24393277.

Population: Adults with grass-pollen allergic rhinitis (n=31)

Dose protocol: 4-week periods with washout

Key findings: Reduced nasal pruritus and selected inflammatory signals

Notes: Primary congestion outcome neutral. Secondary outcomes favorable

Paper content

Reduced nasal pruritus and selected inflammatory signals

lacticaseibacillus-paracasei-SRC-004Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Nuankham K, Sitdhipol J, Chonpathompikunlert P, et al. Impact of Lactocaseibacillus paracasei TISTR 2593 Probiotic Supplementation on the Gut Microbiome of Hypercholesterolemia Patients: A Randomized Controlled Trial. Nutrients. 2024;16(17):2916. doi:10.3390/nu16172916. PMID:39275232.

Population: Adults with hypercholesterolemia.

Dose protocol: L. paracasei TISTR 2593 daily capsules for 90 days

Key findings: Significant LDL cholesterol reduction and favorable microbiome shifts in hypercholesterolemia patients.

Notes: Very small sample (n=22). Adds another strain-specific data point but cannot drive broad claims.

Paper content

This small RCT tested L. paracasei TISTR 2593 daily for 90 days in 22 adults with hypercholesterolemia. The probiotic group showed a significant LDL cholesterol reduction and favorable microbiome shifts, including decreased Subdoligranulum and increased Flavonifractor. While the direction of these findings is encouraging, the very small sample size (n=22) limits confidence in the magnitude and reliability of the LDL effect. This adds another strain-specific data point to the growing but still fragmented L. paracasei evidence base, consistent with the pattern of each strain having a narrow profile tested in only one or two trials.

Guides

Setup

Help